CAH supply chain intelligence for Cardinal Health, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Cardinal Health, Inc. (CAH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | 95% | Reciprocal relationship from CHRS graph: e employees, effective March 10, 2023 for most of these employees. In the first quarter of 2023, non-recurring restructuring charges associated with the reduc… |
| MASI | Masimo Corporation | 95% | Reciprocal relationship from MASI graph: outstanding shares of the Company. The Vice Chairman of the Company’s board of directors, Quentin Koffey, also serves as Chief Investment Officer of Politan. … |
| ADCT | ADC Therapeutics SA | 92% | Reciprocal relationship from ADCT graph: Customers from which we derive more than 10% of our total product revenues for the three months ended March 31, 2026 and 2025 are as follows: Three Months End… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 90% | Reciprocal relationship from AMPH graph: al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current produc… |
| APT | Alpha Pro Tech, Ltd. | 85% | Reciprocal relationship from APT graph: Owens Corning and GAF for synthetic roof underlayment. Our major competitor in the medical and dental markets is Kimberly-Clark Corporation of Fort Worth, Texa… |
| GILD | Gilead Sciences, Inc. | 85% | Reciprocal relationship from GILD graph: Reciprocal relationship from CAH graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CAH graph: Reciprocal relationship from GILD gra… |
| JAGX | Jaguar Health, Inc. | 85% | Reciprocal relationship from JAGX graph: s promise to transfer Mytesi to specialty pharmacies based on specified payment and shipping terms as outlined in the Exclusive Distribution Agreement entered… |
| MGNX | MacroGenics, Inc. | 85% | Reciprocal relationship from MGNX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MGNX graph: es and clinical testing, and regulatory approval prior to commercial use. The… |
| RIGL | Rigel Pharmaceuticals, Inc. | 85% | Reciprocal relationship from RIGL graph: Reciprocal relationship from CAH graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from CAH graph: Reciprocal relationship from RIGL gra… |
| ARDX | Ardelyx, Inc. | 72% | Reciprocal relationship from ARDX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from ARDX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from ARDX gra… |
| COR | Cencora, Inc. | 72% | Reciprocal relationship from COR graph: sed to manage the majority of its transactional volume. The warehouse operating systems have improved U.S. Healthcare Solutions’ productivity and operating lev… |
| CVS | CVS Health Corporation | 72% | Reciprocal relationship from CVS graph: ss is highly competitive. The Company believes that it competes principally on the basis of: (i) store location and convenience, (ii) customer service and sati… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: Reciprocal relationship from CAH graph: Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distri… |
| GRDN | Guardian Pharmacy Services, Inc. | 72% | Reciprocal relationship from GRDN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from GRDN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from GRDN gra… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. opera… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the ava… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from CAH graph: Reciprocal relationship from LLY graph: ng at medical meetings. In addition, we advertise certain products directly to … |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from CAH graph: Reciprocal relationship from MCK graph:… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: . Includes cumulative translation adjustments. Amount in 2025 includes the reversal of $ million for a Zerbaxa (ceftolozane and tazobactam) sales-based milesto… |
| PCRX | Pacira BioSciences, Inc. | 72% | Reciprocal relationship from PCRX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from PCRX graph: s of the partnership, LG Chem has the exclusive rights to commercialize EXPAR… |
| PFE | Pfizer Inc. | 72% | Reciprocal relationship from PFE graph: ed with sales recorded in 2022, related to the expected return of an estimated million treatment courses of EUA-labeled U.S. government inventory. In the first… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN gra… |
| VTRS | Viatris Inc. | 72% | Reciprocal relationship from VTRS graph: posal & impairment charges ( ) Impairment of goodwill ( ) Research and development ( ) Acquired IPR&D ( ) Litigation settlements and other contingencies, net … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-DEFENSE | USGOV-DEPARTMENT-OF-DEFENSE | 95% | USAspending awards from Department of Defense: $901,503 across 3 awards. SPE2DU26F0Y26 4570886442!PHARM PRIME VENDOR FLEET; SPE2DU26F0H27 4570188256!PHARM PRIME VENDOR FLEET; SPE2DX25FQNQU 4568214610… |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $231,198 across 1 awards. 75N90025P00449 SIRTURO (BEDAQUILINE) DRUG TABLETS FROM CARDINAL HEALTH 108, LLC:1296676 [25-000022] | Qwen c… |
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $2,994,125 across 6 awards. 36C24624P0018 RADIOPHARMACEUTICALS; 36C24720N0437 RADIOPHARMACEUTICAL ISOTOPES FUNDING DOCUMENT; 36C24123P0019 VARI… |
| GRDN | Guardian Pharmacy Services, Inc. | 92% | Reciprocal relationship from GRDN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from GRDN graph: a “distinct pharmacy setting” and requires payors to compensate designated lo… |
| HRMY | Harmony Biosciences Holdings, Inc. | 92% | Reciprocal relationship from HRMY graph: Reciprocal relationship from CAH graph: Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and… |
| EXISTING-CUSTOMERS | EXISTING-CUSTOMERS | 90% | Pharma segment revenue for the three months ended March 31, 2026 increased 11 percent to $56.1 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical s… |
| NEW-CUSTOMERS | NEW-CUSTOMERS | 90% | Pharma segment revenue for the nine months ended March 31, 2026 increased 18 percent to $176.0 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sa… |
| CVS | CVS Health Corporation | 85% | Reciprocal relationship from CVS graph: Reciprocal relationship from CAH graph: ability to meet demand may be impacted by supply constraints. Additionally, the recently issued Executive Order titled … |
| CVS | CVS Health Corporation | 85% | ability to meet demand may be impacted by supply constraints. Additionally, the recently issued Executive Order titled “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” … |
| AMBULATORY-SURGERY-CENTERS | AMBULATORY-SURGERY-CENTERS | 80% | distribute medical products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. |
| CLINICAL-LABORATORIES | CLINICAL-LABORATORIES | 80% | distribute medical products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. |
| HOSPITALS | HOSPITALS | 80% | distribute medical products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. |
| OTHER-HEALTHCARE-PROVIDERS | OTHER-HEALTHCARE-PROVIDERS | 80% | distribute medical products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current produc… |
| APT | Alpha Pro Tech, Ltd. | 72% | Reciprocal relationship from APT graph: We manufacture, cut, warehouse and ship disposable protective apparel products and face shields in a 137,500 square foot facility in Nogales, Arizona. The majo… |
| COR | Cencora, Inc. | 72% | Reciprocal relationship from COR graph: Reciprocal relationship from CAH graph: Reciprocal relationship from COR graph: . We will continue to invest in advanced information systems and automated ware… |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S.… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced b… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: Reciprocal relationship from CAH graph: Reciprocal relationship from HROW graph: Reciprocal relationship from CAH graph: Reciprocal relationship from HROW gra… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: nternational, national, regional, and local full-line, short-line, and specialty distributors, service merchandisers, self-warehousing chain drug stores, manuf… |
| PCRX | Pacira BioSciences, Inc. | 72% | Reciprocal relationship from PCRX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from PCRX graph: s of the partnership, LG Chem has the exclusive rights to commercialize EXPAR… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN gra… |
| ADVANCED-DIABETES-SUPPLY-GROUP | ADVANCED-DIABETES-SUPPLY-GROUP | 62% | selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This guidance will be effective for us in fiscal 2028 Form 10-K and should be applied on a prospective b… |
| CARDINAL-HEALTH-INC | CARDINAL-HEALTH-INC | 62% | ent revenue by geographic area: Three Months Ended March 31, (in millions) 2026 2025 United States $ 60,542 $ 54,498 International 423 399 Total segment revenue 60,965 54,897 Corporate (1) ( 25 ) ( 1… |
| FUNDING-LLC | FUNDING-LLC | 62% | g value for recent acquisitions. We will continue to evaluate acquisitions and the related reporting units for indicators of impairment. 31 Cardinal Health | Q3 Fiscal 2026 Form 10-Q Notes to Financi… |
| HCSG | Healthcare Services Group, Inc. | 62% | Reciprocal relationship from HCSG graph: Reciprocal relationship from CAH graph: Reciprocal relationship from HCSG graph: Reciprocal relationship from CAH graph: principled leader as we execute our s… |
| HEALTH-CARE-SERVICE-CORPORATION | HEALTH-CARE-SERVICE-CORPORATION | 62% | principled leader as we execute our strategic priorities with a focus on strong governance and long-term value creation.” Ms. Hemingway Hall has served on the Cardinal Health Board since 2013, includ… |
| RED-OAK-SOURCING-LLC | RED-OAK-SOURCING-LLC | 62% | g value for recent acquisitions. We will continue to evaluate acquisitions and the related reporting units for indicators of impairment. 31 Cardinal Health | Q3 Fiscal 2026 Form 10-Q Notes to Financi… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CAH-DEBT | Debt stack $2.8B | 90% | Market cache reports total debt of $2.8B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CAH-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 1434 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HCSG | Healthcare Services Group, Inc. | 100.00 | 1 | ['customer'] |
| CLH | Clean Harbors, Inc. | 100.00 | 2 | |
| AMPH | Amphastar Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ADCT | ADC Therapeutics SA | 100.00 | 1 | ['supplier'] |
| COR | Cencora, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| XYF | X Financial | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CVSI | CV Sciences, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 1 | ['supplier'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| ARDX | Ardelyx, Inc. | 100.00 | 1 | ['supplier'] |